(DL)-3,5-Dimethyltyrosine
(DL)-3,5-Dimethyltyrosine (SMC247-9) is a selective APOBEC3B inhibitor optimized from SMC247, with an IC50 of 50 pM. (DL)-3,5-Dimethyltyrosine binds to the APOBEC3B protein, reduces intracellular APOBEC3B protein abundance partially through a lysosome-dependent pathway, enhances IL-15 expression in tumor cells, and relieves the suppression of CD8+ T cells by tumor cells in an IL-15-dependent manner. (DL)-3,5-Dimethyltyrosine attenuates tumor- and macrophage-derived chemokine-mediated macrophage chemotaxis and inhibits pathological myeloid inflammatory signaling. (DL)-3,5-Dimethyltyrosine inhibits tumor growth in the immune checkpoint blockade-responsive MC38 syngeneic mouse model and produces synergistic effects with anti-PD-L1 in the immune checkpoint blockade-resistant TC-1 tumor model; it also ameliorates anti-PD-1-exacerbated DSS-induced colitis-like intestinal inflammatory injury. (DL)-3,5-Dimethyltyrosine can be used in research related to tumor immunotherapy.
For research use only. We do not sell to patients.
- CAS No.: 88262-44-6
- Formula: C11H15NO3
- Molecular Weight:209.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-15 |
IL-6 |
TNF-α |
In Vitro
(DL)-3,5-Dimethyltyrosine (SMC247-9) is a potent inhibitor of recombinant APOBEC3B enzymatic activity with an IC50 of 50 pM; it preferentially targets APOBEC3B with approximately 340-fold selectivity over APOBEC3A; it exhibits strong direct binding affinity for recombinant APOBEC3B with a KD of 0.3 nM[1].
(DL)-3,5‑Dimethyltyrosine is competitively inhibited for APOBEC3B binding by ssDNA substrate, yielding a KD of 5.4 μM in the presence of 100 μM ssDNA[1].
(DL)-3,5-Dimethyltyrosine (10 μM; 24 h) reduces APOBEC3B protein abundance in KYSE70 cells, potentially through a lysosome-associated turnover process[1].
(DL)-3,5-Dimethyltyrosine (100 μM; 5 min heating) directly binds APOBEC3B in KYSE70 cell lysates[1].
(DL)-3,5-Dimethyltyrosine (0.01-100 μM; 24-72 h) shows no cytotoxicity in KYSE70 cells[1].
(DL)-3,5-Dimethyltyrosine (10 μM; 48 h) decreases APOBEC3B mRNA and increases IL-15 mRNA expression in KYSE70 cells, and promotes IL-15 secretion by KYSE70 cells[1].
(DL)-3,5-Dimethyltyrosine (10 μM; 48 h pretreatment, 72 h coculture) reprograms the KYSE70 secretory microenvironment to promote IL-15-related CD8+ T cell proliferation and effector function; the induced immune remodeling effect is further enhanced by PD-L1 blockade in a human tumor-conditioned medium model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:KYSE70
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Reduced APOBEC3B protein levels in KYSE70 cells.
CQ partially restored APOBEC3B protein abundance, whereas MG132 (HY-13259) showed no obvious rescue effect.
-
Cell Line:KYSE70
-
Concentration:0.01, 0.1, 1, 10, 100 μM
-
Incubation Time:24, 48, 72 h
-
Result:Had no obvious impact on KYSE70 cell viability at concentrations up to 10 μM over 72 h.
-
Cell Line:KYSE70
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Reduced APOBEC3B mRNA expression while increasing IL-15 mRNA expression.
-
Cell Line:KYSE70
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Increased IL-15 secretion after SMC247-9 treatment.
-
Cell Line:Human PBMC-derived CD8+ T cells, KYSE70 cells
-
Concentration:10 μM
-
Incubation Time:48 h pretreatment; 72 h coculture (αIL-15, 10 μg/mL)
-
Result:Conditioned media from SMC247-9-treated KYSE70 cells partially restored proliferation and increased the IFN-γ+ population.
Addition of an IL-15-neutralizing antibody largely abrogated this effect.
-
Cell Line:Human PBMC-derived T cells, KYSE70 cells
-
Concentration:10 μM
-
Incubation Time:48 h pretreatment; 72 h coculture
-
Result:Conditioned media from KYSE70 cells treated with SMC247-9 or anti-PD-L1 each partially alleviated the suppressive effect on T cell proliferation and effector function.
Conditioned media from the combination group supported a stronger proliferative response and higher IFN-γ+ CD8+ T cell frequency than either single-agent group.
Parmacokinetics
| Species | Dose | Route | Tmax | T1/2 |
|---|---|---|---|---|
| Mice[1] | 20 mg/kg | i.p. | 0.5 h | 1.26 h |
In Vivo
(DL)-3,5-Dimethyltyrosine (1-3 mg/kg; i.p.; daily; 24 days) dose-dependently inhibits tumor progression in the anti-PD-L1-unresponsive TC-1 model and is associated with increased CD8+ T cell infiltration and effector activation in the tumor microenvironment[1].
(DL)-3,5-Dimethyltyrosine (1 mg/kg; i.p.; 9 days) alleviates anti-PD-1-exacerbated DSS-induced colitis-like intestinal inflammation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, inoculated subcutaneously with 1 × 106 MC38 cells)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily; 22 days
-
Result:Markedly suppressed tumor growth, as reflected by reduced tumor volume during treatment and lower tumor weight at the study end point.
Increased the proportion of CD3+CD8+ T cells in tumor tissue.
Significantly elevated the frequency of IFN-γ+ CD8+ T cells in tumors, spleen, and draining lymph nodes.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, inoculated subcutaneously with 2 × 105 TC-1 cells)[1]
-
Dosage:1, 3 mg/kg
-
Administration:i.p.; daily; 24 days
-
Result:Suppressed tumor progression in a dose-dependent manner.
Increased the proportion of tumor-infiltrating CD3+CD8+ T cells and IFN-γ+ CD8+ T cells within tumors.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, treated with 3% DSS in drinking water to establish DSS-induced acute colitis aggravated by anti-PD-1 antibody)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; administered on days 1, 4, and 7
-
Result:Alleviated body weight loss induced by combined anti-PD-1 and DSS treatment.
Rescued colon shortening and improved colon tissue morphological injury shown by H&E staining.
Reduced M1/M2 macrophage ratio in colorectal tissues.
Decreased levels of proinflammatory cytokines IL-6 and TNF-α in colorectal tissue homogenates.
Chemical Information
-
CAS No. 88262-44-6
-
Molecular Weight 209.24
-
Formula C11H15NO3
-
SMILES
OC1=C(C)C=C(CC(N)C(O)=O)C=C1C
-
Synonyms
SMC247-9
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)